Search PubMed⌕ Search

Biomedical subjects

B Nordlinger

Publications and source records attributed to B Nordlinger.

167 records · Page 10Linked to original sources
PubMedDate not supplied

[Transplantation of allogeneic hepatocytes without immunosuppression: long-term survival].

UNLABELLED: Hepatocyte transplantation could be an alternative to whole liver transplantation. Allogeneic hepatocytes are rejected if transplanted without immunosuppression. The aim of this study was to transplant allogeneic hepatocytes in the peritoneum and to protect them from rejection by encapsulation in a new semi-permeable membrane. METHODS: rats hepatocytes were encapsulated in hydrogel-based hollow fibers, obtained from AN69 polymer, before being transplanted into the peritoneum of rats. Outcome of allogeneic hepatocytes encapsuled in hollow fibers was compared to that of free allogeneic hepatocytes. Cell viability was assessed by erythrosine exclusion, morphology by electronic microscopy and function by albumin release. RESULTS: Up to 90 days, viability of allogeneic hepatocytes in hollow fibers was above 80%. The morphology remained normal at electronic microscopy. Albumin release was 16.5 +/- 0.3 (day 15), 14.2 +/- 2.0 (day 30), 8.8 +/- 0.1 (day 60) and 11.4 +/- 0.3 mg/24h/10(6) hepatocytes (day 90). Free hepatocytes did not survive at day 15. CONCLUSION: Viability and function of encapsulated allogeneic hepatocytes were maintained up to 90 days after transplantation, without immunosuppression.

Animals↗
PubMedDate not supplied

Study of cyclosporin A blood level during the early post-liver-transplantation period.

Correlations between acute rejection rate, cyclosporin A(CsA) blood level and CsA dose were studied in a group of 58 patients for 1 month following liver transplant. Therapy included prednisolone, azathioprine and CsA administered by continuous IV infusion. Blood CsA levels were measured by high performance liquid chromatography. No patient required renal dialysis. An acute rejection episode was recorded in 24 patients (group 1) between days 4 and 28 (mean 8 days), while 34 patients (group 2) showed no signs of rejection. A significant difference was observed (p < 0.05) between blood CsA levels (mean +/- SEM over the 6 days preceding the rejection episode in group 1 patients, and the first 6 postoperative days in group 2 patients (101 +/- 7 vs 121 +/- 5 ng/ml). The mean daily dose of CsA calculated over the same time period was significantly lower (p < 0.001) in group 1 patients (46 +/- 2 vs 60 +/- 2 mg/day). In addition, over the 8 days following surgery, only 54% of patients in group 1 attained a mean blood CsA level of a least 100 ng/ml, compared to 94% in group 2.

Cyclosporine↗